Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View

Dr. Rebecca Andrews

Primary Care · UCHC

View

Dr. David Bates

General Internal Medicine · BWH

View

Dr. Reema Dbouk

Obesity Medicine · Emory University

View

Dr. Jennifer Paisley

Obesity Medicine · St. Elizabeth Medical Center

View

Dr. Molly Heublein

Primary Care · Clear Medical Clinic

View

Dr. Ryan Mire

Primary Care · Heritage Medical Associates

View

Dr. Alpesh Amin

Hospital Medicine · UCI

View

Dr. Joia Mukherjee

Global Health · Harvard Medical School

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Favorable Antiviral Effect of Metformin on SARS-CoV-2 Viral Load in a Randomized, Placebo-Controlled Clinical Trial of COVID-19.

    Aug 16, 2024DOI: 10.1093/cid/ciae159Journal ArticleCID

    Written by: Carolyn T BramanteKenneth B BeckmanTanvi MehtaAmy B KargerDavid J OddeChristopher J TignanelliJohn B BuseDarrell M JohnsonRay H B WatsonJerry J DanielDavid M LiebovitzJacinda M NicklasKen CohenMichael A PuskarichHrishikesh K BelaniLianne K SiegelNichole R KlattBlake AndersonKatrina M HartmanVia RaoAubrey A HagenBarkha PatelSarah L FennoNandini AvulaNeha V ReddySpencer M EricksonRegina D FrictonSamuel LeeGwendolyn GriffithsMatthew F PullenJennifer L ThompsonNancy E SherwoodThomas A MurrayMichael R RoseDavid R BoulwareJared D HulingCOVID-OUT Study Team

    Find these authors on Roon

    MR
    Dr. Michael Rose
    HIV/AIDS Medicine · Johns Hopkins

    Summary

    BACKGROUND: Metformin has antiviral activity against RNA viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression of protein translation via targeting the host mechanistic target of rapamycin pathway. In the COVID-OUT randomized trial for outpatient coronavirus disease 2019 (COVID-19), metformin reduced the odds of hospitalizations/death through 28 days by 58%, of emergency department visits/hospitalizations/death through 14 days by 42%, and of long COVID through 10 months by 42%.METHODS: COVID-OUT was a 2 × 3 randomized, placebo-controlled, double-blind trial that assessed metformin, fluvoxamine, and ivermectin; 999 participants self-collected anterior nasal swabs on day 1 (n = 945), day 5 (n = 871), and day 10 (n = 775). Viral load was quantified using reverse-transcription quantitative polymerase chain reaction.RESULTS: The mean SARS-CoV-2 viral load was reduced 3.6-fold with metformin relative to placebo (-0.56 log10 copies/mL; 95% confidence interval [CI], -1.05 to -.06; P = .027). Those who received metformin were less likely to have a detectable viral load than placebo at day 5 or day 10 (odds ratio [OR], 0.72; 95% CI, .55 to .94). Viral rebound, defined as a higher viral load at day 10 than day 5, was less frequent with metformin (3.28%) than placebo (5.95%; OR, 0.68; 95% CI, .36 to 1.29). The metformin effect was consistent across subgroups and increased over time. Neither ivermectin nor fluvoxamine showed effect over placebo.CONCLUSIONS: In this randomized, placebo-controlled trial of outpatient treatment of SARS-CoV-2, metformin significantly reduced SARS-CoV-2 viral load, which may explain the clinical benefits in this trial. Metformin is pleiotropic with other actions that are relevant to COVID-19 pathophysiology.CLINICAL TRIALS REGISTRATION: NCT04510194.
    MR

    Dr. Michael Rose

    Internal Medicine · HIV & AIDS Medicine
    Johns Hopkins Hospital
    michaelrose
    Baltimore, MD, USA